Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Warren

Registered Nurse Macon, GA Nurse Practitioner

NPI 1730609694 CMS profile 10554443

101 Preston Ct, Macon, GA 31210

Open in the dashboard

General payments

$5,953

226 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Warren of Macon, GA is reported in the CMS Open Payments database as having received $5,953 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $650 32
2024 General $1,031 42
2023 General $1,384 50
2022 General $1,557 38
2021 General $1,332 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Warren
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Lauren Warren were reported at $650. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Lauren Warren Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,332 $53 $20–$148 $132
2022 $1,557 $53 $21–$146 $149
2023 $1,384 $84 $26–$196 $160
2024 $1,031 $80 $26–$187 $164
2025 $650 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,659 40 payments
  2. Nalu Medical, Inc. $777 1 payment
  3. Collegium Pharmaceutical, Inc. $439 25 payments
  4. Lilly USA, LLC $420 21 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $379 15 payments
  6. Medtronic, Inc. $217 11 payments
  7. Novo Nordisk Inc $193 10 payments
  8. Scilex Pharmaceuticals Inc. $183 12 payments
  9. RedHill Biopharma Inc. $147 12 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $144 7 payments
  11. Other $1,395 72 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,164 224 payments
  2. Travel and Lodging $777 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Nalu Neurostimulation System $777 1 payment
  2. Superion Indirect Decompression System $387 7 payments
  3. JARDIANCE Diabetes $310 11 payments
  4. JARDIANCE Diabetes $277 13 payments
  5. XTAMPZA $267 14 payments
  6. TRULICITY $216 10 payments
  7. TRADJENTA $199 10 payments
  8. SYNJARDY $182 9 payments
  9. WaveWriter Alpha Prime 16 $177 5 payments
  10. ZTLido $170 11 payments
  11. Other $3,379 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

814

Median for Nurse Practitioner: 389

Drug cost

$118,546

Median for Nurse Practitioner: $21,885

Branded share of claims

17.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 53 $36,859
Ozempic Semaglutide Brand 14 $26,168
Mounjaro Tirzepatide Brand 16 $23,065
Buprenorphine Generic 31 $8,290
Ztlido Lidocaine Brand 11 $6,733
Movantik Naloxegol Oxalate Brand 13 $5,199
Gabapentin Generic 131 $1,841
Tramadol Hcl Er Tramadol Hcl Brand 20 $1,811
Tizanidine Hcl Generic 93 $1,454
Pregabalin Generic 63 $1,228

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $78
$78 — —
Tymlos
  • Radius Health, Inc. $75
$75 — —
REXULTI
  • Lundbeck LLC $32
  • Otsuka America Pharmaceutical, Inc. $23
$55 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $42
$42 53 —
MOUNJARO
  • Lilly USA, LLC $40
$40 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record